Endothelin-1 levels predict 3-year survival in patients who have amputation for critical leg ischaemia

British Journal of Surgery

Volumn 92, Issue 11, 2005, Pages 1377-1381

  Newton, D J ^a   Khan, F ^a   McLaren, M ^a   Kennedy, G ^a   Belch, J J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BIOLOGICAL MARKER; HOMOCYSTEINE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASODILATOR AGENT; VON WILLEBRAND FACTOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; HUMAN; LEG AMPUTATION; LEG ISCHEMIA; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SURVIVAL TIME; VASCULAR ENDOTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; AMPUTATION; BIOLOGICAL MARKERS; COHORT STUDIES; CRITICAL ILLNESS; ENDOTHELIN-1; FEMALE; HUMANS; ISCHEMIA; LEG; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 27544433096     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.5144     Document Type: Article

References (32)

1. Wolfe JHN. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986; 73: 321 (Abstract).
2. Cheng SWK, Ting ACW, Lau H, Wong J. Survival in patients with chronic lower extremity ischemia: a risk factor analysis. Ann Vasc Surg 2000; 14: 158-165.
3. Walker SR, Yusuf SW, Hopkinson BR. A 10-year follow-up of patients presenting with ischaemic rest pain of the lower limbs. Eur J Vasc Endovasc Surg 1998; 15: 478-482.
4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
5. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF III, Graor RA et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-233.
6. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991; 68: 1027-1034.
7. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41: 1769-1775.
8. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.
9. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-1572.
10. Second European Consensus Document on chronic critical limb ischemia. Circulation 1991; 84(Suppl IV): 1-26.
11. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998; 98: 2108-2116.
12. Wald DS, Law M, Morris JK, Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202-1208.
13. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995; 95: 2426-2431.
14. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC). Circulation 1997; 96: 4219-4225.
15. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk In Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-1734.
16. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
17. Newton DJ, Khan F, Belch JJF. Assessment of microvascular endothelial function in human skin. Clin Sci 2001; 101: 567-572.
18. Khan F, Litchfield SJ, Stonebridge PA, Belch JJ. Lipid-lowering and skin vascular responses in patients with hypercholesterolaemia and peripheral arterial obstructive disease. Vasc Med 1999; 4: 233-238.
19. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337-1344.
20. Kubli S, Waeber B, Dalle-Ave A, Feihl F. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol 2000; 36: 640-648.
21. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
22. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-228.
23. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
24. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990; 322: 205.
25. Cavero PG, Miller WL, Heublein DM, Margulies KB, Burnett JC Jr. Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 1990; 259: F312-F317.
26. Omland T, Terje R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
27. Sütsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98: 2262-2268.
28. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98: 2235-2240.
29. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
30. Tsui JCS, Baker DM, Biecker E, Shaw S, Dashwood MR. Potential role of endothelin 1 in ischaemia-induced angiogenesis in critical limb ischaemia. Br J Surg 2002; 89: 741-747.
31. Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Curr Hypertens Rep 2003; 5: 144-148.
32. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.